medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2008, Number 10

<< Back Next >>

Ginecol Obstet Mex 2008; 76 (10)

Relation between fresh plasma administration and morbidity in patients with HELLP syndrome

Montoya RJM, Pacheco CRM, Cortés FR, Hernández HRJ

Language: Spanish
References: 24
Page: 582-586
PDF size: 165.22 Kb.


ABSTRACT

Introduction: HELLP syndrome is a complication of severe preeclampsia; its incidence goes from 0.1 to 0.6% of pregnancies, and causes complications in 4% of patients.
Objective: To evaluate frozen fresh plasma administration to prevent pregnancy complications in patients with HELLP syndrome.
Patients and methods: Retrospective, comparative and non-randomized study. Patients with HELLP syndrome were divided in two groups: first one (n = 23) was treated with fresh frozen plasma (10 mL/kg/day), and second one (n = 29) with dexamethasone. Complications, dialysis requirement, hospital stay, and mortality were compared (χ2 test was used).
Results: Group 1 (n = 23) had nine patients with HELLP syndrome type I, and 14 with type II. Group 2 (n = 29) had 20 cases with HELLP syndrome type I, and nine with type II. Most frequent complication in group 1 was acute renal failure (22%), and hospital stay was 4.5 days. Group 2 had 13 patients with acute renal failure, three with pulmonary edema, one with cerebral edema, one with hepatic fracture, and one with placenta detachment. Hospital stay was from 8 to 30 days (p ‹ 0.002). There were no maternal deaths in both groups.
Conclusions: Fresh frozen plasma meaningfully reduces (43%) complications, hospital stay, and hemodialysis requirement (45%) in patients with HELLP syndrome.


REFERENCES

  1. Cunningham FG, McDonald PC, Gant NF. Hypertensive disorders in pregnancy. In: Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, editors. Williams Obstetrics. 20th ed. Norwalk: Appleton & Lange, 1997;pp:693-744.

  2. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990;162:311-6.

  3. Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing severe preeclampsia in the second trimester. Am J Obstet Gynecol 1990;163:733-8.

  4. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks’ gestation: a randomized controlled trial. Obstet Gynecol 1990;76:1070-5.

  5. Sibai BM, Spinnato JA, Watson DL, Hill GA, Anderson GD. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol 1984;64:319-25.

  6. Martin TR, Tupper WR. The management of severe toxemia in patients at less than 36 weeks’ gestation. Obstet Gynecol 1979;54:602-5.

  7. Moodley J, Koranteng SA, Rout C. Expectant management of early onset of severe preeclampsia in Durban. S Afr Med J 1993;83:584-7.

  8. Olah KS, Redman CW, Gee H. Management of severe early pre-eclampsia: is conservative management justified? Eur J Obstet Gynecol Reprod Biol 1993;51:175-80.

  9. Schiff E, Friedman SA, Sibai BM. Conservative management of severe preeclampsia remote from term. Obstet Gynecol 1994;84:626-30.

  10. Shumak KH, Rock GA. Therapeutic plasma exchange. N Engl J Med 1984;310:762-71.

  11. Watson WJ, Katz VL, Bowes WA. Plasmapheresis during pregnancy. Obstet Gynecol 1990;76:451-7.

  12. d’ Apice AJ, Reti LL, Pepperell RJ, Fairley KF, Kincaid-Smith P. Treatment of severe pre-eclampsia by plasma exchange. Aust N Z J Obstet Gynaecol 1980;20:231-5.

  13. Gupta S, Funkhouser JW. Treatment of thrombotic thrombocytopenic purpura with plasma exchange: five cases. J Clin Apher 1984;2:195-9.

  14. Katz VL, Watson WJ, Thorp JM, Hansen W, Bowes WA. Treatment of persistent postpartum HELLP syndrome with plasmapheresis. Am J Perinatol 1992;9:120-2.

  15. Martin JN, Files JC, Blake PG, Perry KG, et al. Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP. Am J Obstet Gynecol 1995;172:1107-25.

  16. Van Hook JW. Management of complicated preeclampsia. Sem Perinatol 1999;23:79-90.

  17. Rock GA, Shumak KH, Buskard NA, Blanchette VS, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Eng J Med 1991;325:393-7.

  18. Martin JN, Files JC, Blake PG, Norman PH, et al. Plasma exchange for preeclampsia. I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. Am J Obstet Gynecol 1990;162:126-37.

  19. Baxter J, Weinstein L. HELLP syndrome: the state of art. Obstet Gynecol Surv 2004;59:838-45.

  20. Martin JN, Blake PG, Perry KG, McCaul JF, et al. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991;164:1500-13.

  21. Heimel R, Franx A, Schobben A, Huisjes A, et al. Corticosteroids, pregnancy, and HELLP syndrome: a review. Obstet Gynecol Surv 2004;60:57-70.

  22. Obrien JM, Barton J. Controversies with the diagnosis and management of HELLP syndrome. Clin Obstet Gynecol 2005;48:460-77.

  23. Romero JF, Lara AL, Ramos JC, Izquierdo JC. Morbimortalidad materna en síndrome de HELLP. Ginecol Obstet Méx 2001;69:189-93.

  24. Basavilvazo A, Pacheco C, Lemus R, Martínez JM y col. Complicaciones quirúrgicas maternas y perinatales en pacientes con plaquetopenia por síndrome de HELLP, en preclampsia severa-eclampsia en terapia intensiva. Ginecol Obstet Méx 2003;71:379-86.




2020     |     www.medigraphic.com